The biopharmaceutical company has created a rapid injection, anti-toxin antibody called Anthim, which has been proven effective in multiple animal studies and clinical safety trials. Anthim is designed to treat anthrax exposure following a natural or intentional release of anthrax spores, as well as biodefense, cancer, lupus nephritis, infectious diseases, and thrombosis.